0.00Open0.00Pre Close0 Volume0 Open Interest20.00Strike Price0.00Turnover1211.36%IV-132.83%PremiumDec 13, 2024Expiry Date11.41Intrinsic Value100Multiplier1DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.8772Delta0.0407Gamma0.74Leverage Ratio-0.5843Theta-0.0004Rho-0.65Eff Leverage0.0008Vega
Altimmune Stock Discussion
Altimmune Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) at The Liver Meeting® 2024
Altimmune (Nasdaq: ALT) presented new data from its 12-week Phase 1b trial of pemvidutide in MASLD patients at The Liver Meeting®.
The study demonstrated that weekly subcutaneous doses of pemvidutide significantly reduced inflammatory lipids and showed promising effects on cardiovascul...
Larger Image: tradingview.com...
$Altimmune (ALT.US)$
Will a partner be announced or are the rumours true a buy out is eminent..!
Larger Image: tradingview.com...
$Altimmune (ALT.US)$
No comment yet